Literature DB >> 21295878

HDR monotherapy for prostate cancer: a simulation study to determine the effect of catheter displacement on target coverage and normal tissue irradiation.

Inger-Karine K Kolkman-Deurloo1, Martin A Roos, Shafak Aluwini.   

Abstract

PURPOSE: The aim of this study was to systematically analyse the effect of catheter displacements both on target coverage and normal tissue irradiation in fractionated high dose rate (HDR) prostate brachytherapy, using a simulation study, and to define tolerances for catheter displacement ensuring that both target coverage and normal tissue doses remain clinically acceptable. Besides the effect of total implant displacement, also displacements of catheters belonging to selected template rows only were evaluated in terms of target coverage and normal tissue dose, in order to analyse the change in dose distribution as a function of catheter dwell weight and catheter location.
MATERIAL AND METHODS: Five representative implant geometries, with 17 catheters each, were selected. The clinical treatment plan was compared to treatment plans in which an entire implant displacement in caudal direction over 3, 5, 7 and 10 mm was simulated. Besides, treatment plans were simulated considering a displacement of either the central, most ventral or most dorsal catheter rows only, over 5 mm caudally.
RESULTS: Due to displacement of the entire implant the target coverage drops below the tolerance of 93% for all displacements studied. The effect of displacement of the entire implant on organs at risk strongly depended on the patient anatomy; e.g., for 80% of the implant geometries the V(80) of the rectum exceeded its tolerance for all displacements. The effect of displacement of catheters belonging to selected template rows depended strongly on the relative weight of each catheter row when considering the target coverage and on its location when considering the dose in the organs at risk.
CONCLUSION: This study supports the need for a check of the catheter locations before each fraction and correction of deviations of the catheter position exceeding 3mm.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21295878     DOI: 10.1016/j.radonc.2010.12.009

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

Review 1.  The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.

Authors:  Yasuo Yoshioka; Ken Yoshida; Hideya Yamazaki; Norio Nonomura; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2013-03-29       Impact factor: 2.724

Review 2.  High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective.

Authors:  Yasuo Yoshioka; Osamu Suzuki; Yuki Otani; Ken Yoshida; Takayuki Nose; Kazuhiko Ogawa
Journal:  J Contemp Brachytherapy       Date:  2014-04-03

3.  The impact of activating source dwell positions outside the CTV on the dose to treated normal tissue volumes in TRUS guided 3D conformal interstitial HDR brachytherapy of prostate cancer.

Authors:  Leif Karlsson; Per Thunberg; Bengt Johansson; Jan Persliden
Journal:  J Contemp Brachytherapy       Date:  2014-09-23

Review 4.  Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM.

Authors:  Christian Kirisits; Mark J Rivard; Dimos Baltas; Facundo Ballester; Marisol De Brabandere; Rob van der Laarse; Yury Niatsetski; Panagiotis Papagiannis; Taran Paulsen Hellebust; Jose Perez-Calatayud; Kari Tanderup; Jack L M Venselaar; Frank-André Siebert
Journal:  Radiother Oncol       Date:  2013-11-30       Impact factor: 6.280

5.  Catheter displacement prior to the delivery of high-dose-rate brachytherapy in the treatment of prostate cancer patients.

Authors:  Shogo Kawakami; Hiromichi Ishiyama; Tsuyoshi Terazaki; Itaru Soda; Takefumi Satoh; Masashi Kitano; Shinji Kurosaka; Akane Sekiguchi; Shouko Komori; Masatsugu Iwamura; Kazushige Hayakawa
Journal:  J Contemp Brachytherapy       Date:  2014-06-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.